| scholarly article | Q13442814 |
| P50 | author | Kenneth C. Anderson | Q28421846 |
| P2093 | author name string | Robert Smith | |
| Nikhil C Munshi | |||
| Yu-Tzu Tai | |||
| Weihua Song | |||
| John Daley | |||
| Jooeun Bae | |||
| P2860 | cites work | Plasma cell differentiation requires the transcription factor XBP-1 | Q24291453 |
| Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family | Q24291883 | ||
| An operational definition of epigenetics | Q24568002 | ||
| Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells | Q24601584 | ||
| LDL-receptor-related protein 6 is a receptor for Dickkopf proteins | Q28116567 | ||
| Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program | Q28216493 | ||
| The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma | Q28236113 | ||
| Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity | Q33562557 | ||
| A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma | Q33829132 | ||
| Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily | Q33935576 | ||
| Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. | Q34248627 | ||
| Novel biologically based therapies for myeloma | Q34336603 | ||
| Lenalidomide and thalidomide: mechanisms of action--similarities and differences | Q34475254 | ||
| The molecular classification of multiple myeloma | Q34530992 | ||
| A clinical development paradigm for cancer vaccines and related biologics | Q34596591 | ||
| Oxygen-Dependent Gene Expression in Development and Cancer: Lessons Learned from the Wilms' Tumor Gene, WT1 | Q34617481 | ||
| Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia | Q35070558 | ||
| In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response. | Q35198753 | ||
| CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma | Q35610286 | ||
| A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy | Q35968482 | ||
| Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies | Q36757181 | ||
| Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu | Q36835070 | ||
| Cancer vaccines: a promising cancer therapy against all odds | Q36839778 | ||
| Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma | Q37089674 | ||
| Paradigm shifts in cancer vaccine therapy. | Q37122893 | ||
| Strategies used for MUC1 immunotherapy: preclinical studies | Q37259594 | ||
| Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma | Q37357340 | ||
| Epitope discovery and their use in peptide based vaccines | Q37778086 | ||
| Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. | Q37835572 | ||
| Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders | Q39477274 | ||
| Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma | Q39527323 | ||
| Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination | Q40174966 | ||
| Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. | Q40386434 | ||
| Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells | Q44607712 | ||
| Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis | Q44834826 | ||
| Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix | Q46685402 | ||
| Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 | ||
| Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity. | Q51594923 | ||
| Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma. | Q51692601 | ||
| Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. | Q51888426 | ||
| A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. | Q53246749 | ||
| CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. | Q54053672 | ||
| Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H | Q71257873 | ||
| Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities | Q81482089 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cytotoxicity | Q246181 |
| lymphocyte | Q715347 | ||
| P304 | page(s) | 687-701 | |
| P577 | publication date | 2012-04-26 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma | |
| P478 | volume | 157 |
| Q34543937 | A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients |
| Q50038027 | Advances in CAR- T therapy for patients with multiple myeloma |
| Q92710260 | BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications |
| Q37666309 | CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma |
| Q27023621 | Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic |
| Q42979673 | Dendritic cell cancer vaccines: from the bench to the bedside |
| Q33992425 | Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells |
| Q47580433 | Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma |
| Q42287234 | Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma |
| Q38580545 | Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies |
| Q38177879 | Immunotherapy for multiple myeloma |
| Q38809499 | Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab |
| Q39084427 | Is immunotherapy here to stay in multiple myeloma? |
| Q37340304 | Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders |
| Q37010531 | Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment |
| Q33958520 | New strategies in the treatment of multiple myeloma |
| Q39389614 | Novel anti-myeloma immunotherapies targeting the SLAM family of receptors |
| Q35628678 | Profile of elotuzumab and its potential in the treatment of multiple myeloma |
| Q92372452 | Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy |
| Q52584346 | Signaling lymphocytic activation molecules Slam and cancers: friends or foes? |
| Q38246639 | T cell-based targeted immunotherapies for patients with multiple myeloma |
Search more.